One-year cost of Ado-trastuzumab emtansine

Ado-trastuzumab emtansine is used to treat HER2-positive metastatic breast cancer (cancer that has spread) in patients who have not responded to previous treatments with other drugs (such as trastuzumab, taxanes) or whose cancer has recurred during or within 6 months of completing treatment. It is also used as an add-on treatment for patients with HER2-positive early-stage breast cancer who still have cancer after treatment with taxane drugs and trastuzumab.

This drug should only be taken by a physician or under the direct supervision of a physician. Patients treated with trastuzumab may develop hepatotoxicity, liver failure, reduced left ventricular ejection fraction, and death. Monitor liver function and left ventricular function before initiating treatment and before each dose. Modify, suspend or interrupt treatment as necessary. Exposure to trastuzumab during pregnancy can cause embryo-fetal damage. Inform patients of these risks and the need for effective contraception.

EnmetratrastuzumabThe monoclonal antigenic drug has been launched in China and has entered the scope of medical insurance. It can only be reimbursed by qualified patients. It is a strictly controlled drug. SpecificationsThe price of each box of 100mg may be around 20,000 yuan. This drug is used once every three weeks at 3.6mg/kg, which may cost hundreds of thousands of yuan a year. The price is very expensive. Listed overseas Enmei Trastuzumab The single-unit generic drug has Turkish and European versions, with specifications The price of each box of 100 mg may be around 3,000-8,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of the originator drugs sold domestically and abroad are basically the same, and there are currently no generic versions of Enmei Trastuzumab produced and launched.